Corrections Policy
How GeneAnalyses evaluates and records factual corrections.
Last updated 2 September 2026
What we correct
We correct factual errors, unsupported certainty, misplaced cancer-type or treatment-setting claims, broken or mismatched references, and language that could cause a reader to interpret educational content as personal medical advice.
How corrections are handled
Potential issues are checked against the most direct available evidence. Minor spelling or formatting fixes may be made silently. Material corrections should update the page date and be summarised below with the affected page, the original problem, and the correction.
Correction log
10 September 2026 — EGFR, HER2, BRCA1 and TP53 mechanism corrections
EGFR profile: corrected the ligand-binding site from domains II/IV to the interface between domains I/III, and replaced the unsupported “~100-fold” T790M claim with the primary biochemical finding that ATP affinity increases by more than an order of magnitude.
HER2 profile: corrected the HER2–HER3 activator/receiver roles, removed the claim that HER2 lacks autophosphorylation capacity, and narrowed the trastuzumab mechanism.
BRCA1 profile: distinguished inherited monoallelic predisposition from tumour biallelic loss and removed advice implying that a BRCA reversion alone supports switching to platinum.
TP53 profile: narrowed hotspot wording so dominant-negative and gain-of-function effects are not presented as universal properties of every missense variant.
Evidence: EGFR–EGF structure, EGFR T790M biochemistry, HER2–HER3 kinase roles, BRCA reversion resistance, and TP53 dominant-negative and gain-of-function review.
30 August 2026 — site-wide evidence and wording review
Clarified the cancer type and response-rate context for adagrasib plus cetuximab; corrected progression-free-survival wording for capivasertib; narrowed overgeneralised anti-EGFR and inherited-risk statements; and added explicit AI-assistance and clinical-review disclosures.
Reporting an issue
Use the Report an issue guide. Include the affected page, exact sentence, reason for concern and the strongest direct source you can provide. The current public contact channel is the GeneAnalyses newsletter publication; no private address is published without the owner’s consent.